These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7990854)

  • 41. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism.
    Calabrese VP; Lloyd KA; Brancazio P; Cefali E; Martin P; Wall J; Sica D
    Mov Disord; 1998 Sep; 13(5):768-74. PubMed ID: 9756144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1992 Jul; 55(7):630-1. PubMed ID: 1386383
    [No Abstract]   [Full Text] [Related]  

  • 43. Dynorphin agonist therapy of Parkinson's disease.
    Giuffra M; Mouradian MM; Davis TL; Ownby J; Chase TN
    Clin Neuropharmacol; 1993 Oct; 16(5):444-7. PubMed ID: 8106151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Parkinson's disease with NADH.
    Dizdar N; Kågedal B; Lindvall B
    Acta Neurol Scand; 1994 Nov; 90(5):345-7. PubMed ID: 7887134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.
    Martignoni E; Pacchetti C; Sibilla L; Bruggi P; Pedevilla M; Nappi G
    Clin Neuropharmacol; 1991 Feb; 14(1):78-83. PubMed ID: 1903079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologic properties of (-)-3PPP (preclamol) in man.
    Tamminga CA; Cascella NG; Lahti RA; Lindberg M; Carlsson A
    J Neural Transm Gen Sect; 1992; 88(3):165-75. PubMed ID: 1358119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
    Irwin RP; Nutt JG; Woodward WR; Gancher ST
    Clin Neuropharmacol; 1992 Oct; 15(5):365-74. PubMed ID: 1423336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modifications of sleep parameters in the rat by (+)- and (-)-3-PPP.
    Kafi-de St Hilaire S; Sovilla JY; Hjorth S; Gaillard JM
    J Neural Transm; 1985; 62(3-4):209-17. PubMed ID: 4031842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
    Cannon JG; Kirschbaum KS; Amoo VE; Johnson AK; Long JP
    J Med Chem; 1993 Aug; 36(16):2416-9. PubMed ID: 8103114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drugs acting on dopamine receptors: usefulness of a peripheral blocker in Parkinson's disease.
    Corsini GU; Del Zompo M; Tocco F; Arca P; Gessa GL
    Pharmacol Res Commun; 1980 Jul; 12(7):699-707. PubMed ID: 7403240
    [No Abstract]   [Full Text] [Related]  

  • 51. A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease.
    Tsui JK; Wolters EC; Peppard RF; Calne DB
    Neurology; 1989 Jun; 39(6):856-8. PubMed ID: 2725884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of N1-dansylspermine and Ro25,6981 on locomotor activity in naive mice and in the reserpinized mouse model of Parkinson's disease.
    Devadasan C; Starr B; Doyle KM
    Neuroreport; 2016 Dec; 27(17):1243-1247. PubMed ID: 27653937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application.
    Birkmayer JG; Vrecko C; Volc D; Birkmayer W
    Acta Neurol Scand Suppl; 1993; 146():32-5. PubMed ID: 8101414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Anticholinergical treatment of brain injury. Results of 2 decades].
    Heppner F; Argyropoulos G; Lanner G
    Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed; 1973 Aug; 76(8):341-59. PubMed ID: 4272093
    [No Abstract]   [Full Text] [Related]  

  • 55. [Possibility of occurrence of psychoses after pridinol treatment].
    Cichecki Z
    Psychiatr Pol; 1980; 14(1):88-9. PubMed ID: 7367525
    [No Abstract]   [Full Text] [Related]  

  • 56. Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.
    Muralikrishnan D; Ebadi M; Brown-Borg HM
    Neurochem Res; 2004 Feb; 29(2):379-84. PubMed ID: 15002733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
    Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN
    Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.